資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31665
|
| 標題: | A histone deacetylase inhibitor enhances expression of genes inhibiting Wnt pathway and augments activity of DNA demethylation reagent against nonsmall-cell lung cancer |
| 作者: | Shieh, Jiunn-Min
Tang, Yen-An
Hu, Fu-Han
Huang, Wei-Jan
Wang, Ying-Jan
Jen, Jayu
Liao, Sheng-You
Lu, Ying-Hung
Yeh, Ya-Ling
Wang, Tseng-Wei
Lin, Pinpin
Wang, Yi-Ching |
| 貢獻者: | Chi Mei Med Ctr, Div Chest Med, Dept Internal Med
Chia Nan Univ Pharm & Sci, Ctr Gen Educ
Natl Cheng Kung Univ, Inst Basic Med Sci
Natl Cheng Kung Univ, Dept Pharmacol
Taipei Med Univ, Grad Inst Pharmacognosy
Natl Cheng Kung Univ, Dept Environm & Occupat Hlth
Natl Hlth Res Inst, Natl Inst Environm Hlth Sci |
| 關鍵字: | histone deacetylase inhibitor
5-aza-2-deoxycytidine
Wnt signal
lung cancer |
| 日期: | 2017-05-15 |
| 上傳時間: | 2018-11-30 15:52:06 (UTC+8) |
| 出版者: | Wiley |
| 摘要: | Development of new inhibitors targeting histone deacetylases (HDACs) with improved efficacy for solid tumor therapy is urgently needed. Here, we report the development of a novel HDAC inhibitor TMU-35435 and verify it as a single agent and in combination treatment with DNA demethylation reagent 5-aza-2-deoxycytidine (5-aza-dC) in lung cancer preclinical models. TMU-35435 exerted cancer-specific cytotoxicity via mitochondria-mediated apoptosis. Expression microarrays revealed a unique TMU-35435-induced gene networks enriched in biological processes, including negative regulation of cell proliferation and Wnt receptor signaling pathway compared to FDA-approved HDAC inhibitor SAHA. TMU-35435 inhibited tumor growth with good pharmacokinetic properties and safety features in lung orthotopic and subcutaneously implanted xenograft models. TMU-35435 and 5-aza-dC showed synergistic antitumor effects through reactivation of tumor suppressor genes and those genes encoding negative regulators of Wnt signaling pathway in vitro and in vivo. Some genes showed additive inhibition of DNA methylation upon TMU-35435 and 5-aza-dC combined treatment. Our findings suggested that TMU-35435 is a potential HDAC inhibitor for lung cancer treatment as a single agent and in combination with 5-aza-dC. What's new? Histone deacetylases (HDACs) fill a critical role in the epigenetic regulation of gene expression. In cancer, however, their over activity contributes to aberrant gene expression and tumor growth. HDAC inhibition is therefore an appealing therapeutic avenue. Here, a novel HDAC inhibitor, TMU-35435, when administered as a single agent in preclinical lung cancer models, effectively inhibited tumor growth. Given together with a DNA demethylation reagent, TMU-35435 acted synergistically to induce cell death via reduced DNA methylation and reactivation of tumor suppressor genes that encode negative Wnt signaling regulators. Safety profiles in mice further highlight the potential of TMU-35435 as a cancer therapy. |
| 關聯: | International Journal of Cancer, v.140, n.10, pp.2375-2386 |
| 顯示於類別: | [通識教育中心] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| ijc.30664.pdf | | 1453Kb | Adobe PDF | 0 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1586 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
